Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(15)
•••
Comment by PinnacleXon Oct 08, 2019 11:01am
142 Views
Post# 30207137

RE:RE:Almost no growth in revenues for Q3

RE:RE:Almost no growth in revenues for Q3
SPCEO1 wrote: Looks like the Bloomberg total sales numbers were clsoer to being accurate than the Taimed monthly sales numbers. Still, I have no good explanation for how they could add so many new patients (according to Bloomberg) and not have a better sales performance unless they are also simultaneously losing patients. And you would not think they would be adding patients if doctors are pulling other patients off the drug. Hopefully, we will learn something on the conference call that would make some sense of this.  On the postive side, they kept expenses under control. 

jfm1330 wrote: 15.6 M$ in Q2 to 16.1 M$ in Q3. The revenues from Trogarzo are not in the PR. Not good.




So was I wrong all along you ignorant fanboy? Nothing but lies from these morons and crooks nothing else. Horrendous miss no sales no bottom until high 3 bucks that's $3 funking dollars
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities